These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17855189)
1. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. Syrigos KN; Karapanagiotou E; Charpidou A; Dilana K; Dannos I; Dionellis G; Rigopoulou A; Georgatou N; Roussos C J Chemother; 2007 Aug; 19(4):438-43. PubMed ID: 17855189 [TBL] [Abstract][Full Text] [Related]
2. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Syrigos KN; Dannos I; Dionellis G; Bofos I; Alamara C; Dimakou E; Stratakos G; Papiris S Anticancer Res; 2005; 25(5):3489-93. PubMed ID: 16101167 [TBL] [Abstract][Full Text] [Related]
3. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V; Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489 [TBL] [Abstract][Full Text] [Related]
4. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer. Karapanagiotou EM; Charpidou A; Tzannou I; Dilana K; Kotteas E; Tourkantonis I; Kosmas E; Provata A; Syrigos K Med Oncol; 2008; 25(3):303-8. PubMed ID: 18204976 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825 [TBL] [Abstract][Full Text] [Related]
8. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Syrigos KN; Konstantinou M; Sepsas E; Papamichales G; Loullias A; Belenis I; Skottis I; Charpidou A; Roussos C Anticancer Res; 2007; 27(4C):2887-92. PubMed ID: 17695466 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537 [TBL] [Abstract][Full Text] [Related]
12. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Neubauer MA; Garfield DH; Kuerfler PR; Raju RN; Lindquist DL; Soo EW; Khan M; Boehm KA; Asmar L; Lung Cancer; 2005 Jan; 47(1):121-7. PubMed ID: 15603862 [TBL] [Abstract][Full Text] [Related]
13. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Galetta D; Gebbia V; Giotta F; Durini E; Romito S; Borsellino N; Cazzato C; Pezzella G; Colucci G Lung Cancer; 2002 Oct; 38(1):79-84. PubMed ID: 12367797 [TBL] [Abstract][Full Text] [Related]
15. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Tibaldi C; Vasile E; Antonuzzo A; Di Marsico R; Fabbri A; Innocenti F; Tartarelli G; Amoroso D; Andreuccetti M; Lo Dico M; Falcone A Br J Cancer; 2008 Feb; 98(3):558-63. PubMed ID: 18212755 [TBL] [Abstract][Full Text] [Related]
16. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259 [TBL] [Abstract][Full Text] [Related]
17. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. Fidias PM; Dakhil SR; Lyss AP; Loesch DM; Waterhouse DM; Bromund JL; Chen R; Hristova-Kazmierski M; Treat J; Obasaju CK; Marciniak M; Gill J; Schiller JH J Clin Oncol; 2009 Feb; 27(4):591-8. PubMed ID: 19075278 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Park SH; Hong J; Kim YS; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Park J; Cho EK; Shin DB; Lee JH Lung Cancer; 2008 Oct; 62(1):72-7. PubMed ID: 18342982 [TBL] [Abstract][Full Text] [Related]
19. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA; Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]